ContraFect Corporation

(CFRX) Trade

By |

Profile

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

Contact Information

Website: www.contrafect.com
Email: invest@contrafect.com
Main Phone: +1 914 207-2300
Address: 28 Wells Avenue
Address 2: 3rd Floor
State: NY
City / Town: Yonkers
Country: USA
Postal Code: 10701

Issuer Information

Exchange: NSC
CEO: Roger J. Pomerantz
Employees: 20
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

Contact Information

Website: www.contrafect.com
Email: invest@contrafect.com
Main Phone: +1 914 207-2300
Address: 28 Wells Avenue
Address 2: 3rd Floor
State: NY
City / Town: Yonkers
Country: USA
Postal Code: 10701

Issuer Information

Exchange: NSC
CEO: Roger J. Pomerantz
Employees: 20
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 0.48 $ 0.0095 (2.03%)
Last Price 0.48 Change $ 0.0095 Change % 2.03 Tick N/A
Bid 0.48 Bid Size 100.00 Ask 0.50 Ask Size 2,200.00
Open 0.47 High 0.50 Low 0.47 Prev Close 0.47
Last Trade Volume 114,511 52 Wk Hi 2.93 52 Wk Low 0.36
Market Cap 37.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 79,409,556.00 EPS (TTM) -0.10 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 12
Number of Buys 0 12
Number of Sells 0 0
Net Activity 0 138800
Last 10 Buys Shares
Michael Messinger 1,000
Joshua Muntner 1,000
Natalie Bogdanos 1,000
Cara Cassino 1,000
Roger J. Pomerantz 1,000
Lisa Ricciardi 1,000
Sol J. Barer 1,000
David N. Low 1,000
Michael J. Otto 1,000
Cary W. Sucoff 1,000
Last 10 Sell Shares
Daniel Couto 1,000
Daniel Couto 1,000
Daniel Couto 1,000
Daniel Couto 1,000
Daniel Couto 1,000
Daniel Couto 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 7 7 7 7
Low Target Price Estimate 3 3 3 2.8
Mean Target Price Estimate 5 5 5 4.27
Standard Deviation 2.83 2.83 2.83 2.37
Date of Most Recent Estimate 05/14/18 05/14/18 05/14/18 06/18/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 2 2 2
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.5 1.67 1.67 1.67